SWOG clinical trial number
S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Open
Phase
Accrual
98%
Abbreviated Title
DART
Status Notes
Permanently Closed to Accrual: 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53.
Temporarily Closed to Accrual: 40, 46.
For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.
Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.
Temporarily Closed to Accrual: 40, 46.
For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.
Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.
Activated
01/13/2017
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Treatment
Ipilimumab
Nivolumab
Eligibility Criteria Expand/Collapse
Please see Section 5.0 of the S1609 protocol.
S1609 cohorts are opened and closed at irregular intervals. Consult the SWOG S1609 Accrual report at: http://www.swogstat.org/accrual/dart.pdf for Cohort status and planned Cohort Closures PRIOR TO CONSENTING PATIENTS to S1609.
S1609 cohorts are opened and closed at irregular intervals. Consult the SWOG S1609 Accrual report at: http://www.swogstat.org/accrual/dart.pdf for Cohort status and planned Cohort Closures PRIOR TO CONSENTING PATIENTS to S1609.
Publication Information Expand/Collapse
2024
PMid: PMID38358334 | PMC number: PMC11309904
PMid: PMID37882676 | PMC number: PMC10842092
PMid: PMID39417692
PMid: PMID39583952 | PMC number: PMC11583498
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial
PMid: PMID38243705 | PMC number: PMC11077308
PMid: PMID39067873 | PMC number: PMC11284838
PMid: PMID39343510 | PMC number: PMC11440191
PMid: PMID39561273
Outcome and Treatment Toxicity at Community versus Academic Sites for Patients with Rare Cancers on Immune Checkpoint Inhibitors (NCI/SWOG S1609)
2023
2022
PMid: PMID34716198 | PMC number: PMC8776596
2021
PMid: PMID33882143 | PMC number: PMC8606104
2020
PMid: PMID31969335 | PMC number: PMC7231627
PMid: PMID33215052 | PMC number: PMC7670562
PMid: PMID32414761
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
18%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase